Weekly review in ophthalmology: 21 May - 27 May

An end-of-week review of what happened in ophthalmology from 21 May to 27 May.

This week, Ophthalmology Times Europe covered a variety of revelations from ARVO 2022, from advancing IOL technology for the treatment of presbyopia to the safety and efficacy of triamcinolone acetonide via suprachoirodal injection and the stimulation of the trigeminal nerve for the treatment of dry eye disease via OC-02.

At Retina World Congress, Prof. Anat Loewenstein presented data regarding the efficacy of faricimab at targeting both the VEGF and Ang2 pathways in patients with neovascular AMD and diabetic macular oedema.

In the surgical realm, Dr Joseph W. Fong and Dr Ahmed A. Sallam discussed the use of a chandelier to shed light on vitreous opacities during cataract surgery. In addition, Dr Abha Amin wrote about mastering the Yamane technique in IOL fixation.

Mastering the Yamane technique: Key learnings from first cases

The Yamane technique, first described by Shin Yamane and colleagues,1 is of use for intrascleral IOL fixation when a patient is aphakic without capsular support. It sparked my interest since I was seeking a solution for cases where iris fixation was not an option.

The technique offers an elegant and effective way to fixate the IOL in complex cases. I have had the opportunity to perform it several times and my first few cases provided me with some key takeaways as well as offering a unique perspective to identify areas for further improvement.

Thorough preparation, including practising in two wet labs before the first case, is a must, and the learning curve with the Yamane technique can be steep. However, it is also short. And whilst mastering a method usually requires a large number of cases, I have achieved great outcomes quickly by going back and reviewing videos and analysing my early experiences.

Read more

Advancing IOL technology for treatment of presbyopia

Ora's Caitlin Black, senior director and therapeutic area head of medical devices, talks about the next generation of ophthalmic device therapies and diagnostics, clinical trial updates and new innovations that are most exciting for presbyopia treatment.

Watch now

Integrated study: Phase 3 PEACHTREE, AZALEA indicate significant BCVA gains, CST reduction

At ARVO 2022, Dr Steven Yeh reviews the results of the Phase 3 PEACHTREE and AZALEA integrated study, revealing significant BCVA gains and low adverse event incidence in the Xipere (triamcinolone acetonide injectable suspension, Bausch + Lomb) arm.

Dr Yeh is a professor of ophthalmology and the Director of Retinal Disease and Uveitis at the Stanley M. Truhlsen Eye Institute at the University of Nebraska Medical Centre.

Watch here

Shedding light on vitreous opacities during cataract surgery

Cataract surgery can be difficult to perform when dense vitreous opacities are present, due to the absence of the red reflex. Even when cataract surgery is combined with vitrectomy, this difficulty still exists because, in many cases, the view is too poor to permit vitrectomy to clear the vitreous opacities before removal of the cataract.

Dr Joseph Fong and Dr Ahmed A. Sallam, both from the Harvey & Bernice Jones Eye Institute at the University of Arkansas for Medical Sciences in Little Rock, Arkansas, United States, shared their pearls for improving the visualisation in these eyes using retroillumination techniques that include a 25-gauge chandelier or a light pipe.

Continue reading

Data reveals efficacy of bispecific targeting of VEGF, Ang2 pathways

At Retina World Congress 2022, Prof. Anat Loewenstein presented a talk entitled, “Targeting the Ang/Tie2 Pathway: Efficacy and Outcomes.” In her presentation, she discussed data for the bispecific molecule faricimab and its efficacy at targeting both the VEGF and Ang2 pathways while treating neovascular age-related macular degeneration (AMD) and diabetic macular oedema (DMO).

Watch the interview

Investigating efficacy of OC-02 to stimulate the trigeminal nerve for the treatment of dry eyes

The study's primary endpoints were to look at increasing Schirmer's scores, as well as eye discomfort score.

Watch the video